Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20167820 | 0.84 | LMNA (0.42) | LMNASMN1; SMN2POLBBCL6IDO1 | |
| SCHEMBL17048154 | 0.83 | LMNA (0.34) | LMNASMN1; SMN2POLBIDO1 | |
| SCHEMBL17048224 | 0.81 | KMT2A (0.37) | LMNASMN1; SMN2CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL25153458 | 0.78 | APP (0.41) | POLBTUBB1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL15682035 | 0.76 | CA2 (0.47) | LMNATUBB1CYP3A4MAPTMRGPRX4 | |
| SCHEMBL10655311 | 0.75 | NPC1 (0.45) | LMNASMN1; SMN2POLBIDO1RXFP1 | |
| SCHEMBL5288288 | 0.74 | LMNA (0.46) | LMNASMN1; SMN2MAPT | |
| SCHEMBL18026870 | 0.74 | POLB (0.51) | POLBMAPT | |
| SCHEMBL20969624 | 0.73 | PDE4B (0.39) | LMNABCL6IDO1L3MBTL1MRGPRX4 | |
| SCHEMBL20149267 | 0.72 | IDO1 (0.36) | LMNASMN1; SMN2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781208-B2 | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-22 | — | — | US | disclosed |
| US-10781208-B2 | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3110815-B1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEV INC (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-20190315741-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315741-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-17 | — | — | US | disclosed |
| EP-3541816-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | The Regents of The University of Michigan (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018094134-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018094134-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-05-24 | — | — | WO | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3110815-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | Jiangsu Ascentage Biomed Development Inc. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | ALK, BCL6, BCL6B | LMNA 809/4885SMN1; SMN2 4778/4885POLB 2284/4885 |
| US-20190315741-A1 | 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS | ALK, KRAS, ABL1 | LMNA 2870/4885SMN1; SMN2 2022/4885POLB 781/4885 |
| US-10781208-B2 | 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors | ALK, KRAS, ABL1 | LMNA 2511/4885SMN1; SMN2 1796/4885POLB 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.